Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

614 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ. Lee M, et al. Among authors: mok j. Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1. Trials. 2019. PMID: 30651149 Free PMC article.
Early discontinuation of ethambutol in pulmonary tuberculosis treatment based on results of the GenoType MTBDRplus assay: A prospective, multicenter, non-inferiority randomized trial in South Korea.
Jo KW, Kim M, Kim YJ, Lee HK, Kim HK, Jeon D, Lyu J, Park HK, Mok J, Kim JS, Heo EY, Choi SB, Yim JJ, Shim TS. Jo KW, et al. Among authors: mok j. Antimicrob Agents Chemother. 2019 Sep 19;63(12):e00980-19. doi: 10.1128/AAC.00980-19. Epub 2019 Sep 16. Antimicrob Agents Chemother. 2019. PMID: 31527020 Free PMC article.
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS. Kim JS, et al. Among authors: mok j. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0168421. doi: 10.1128/AAC.01684-21. Epub 2021 Dec 6. Antimicrob Agents Chemother. 2022. PMID: 34871098 Free PMC article. Clinical Trial.
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort.
Hung TM, Jayanti RP, Lee HY, Kim HJ, Mok J, Jang TW, Oh JY, Kim JS, Ko Y, Min J, Hoa PQ, Ahn S, Long NP, Cho YS, Shin JG; cPMTb. Hung TM, et al. Among authors: mok j. Int J Antimicrob Agents. 2023 Aug;62(2):106840. doi: 10.1016/j.ijantimicag.2023.106840. Epub 2023 May 7. Int J Antimicrob Agents. 2023. PMID: 37160240 Free article.
614 results